Skip to main content
Signal8

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

$GILDPress releaseNov 5, 2026, 10:00 AM ETRead the release

Gilead reported positive Phase 3 IDEAL results for Livdelzi (seladelpar) in PBC patients with milder ALP elevation (1-1.67x ULN) previously excluded from pivotal trials. At Week 52, 75.4% of Livdelzi-treated participants achieved the ALP normalization composite endpoint versus 16.1% on placebo, with response evident within one month and no new safety concerns.

Key figures

Drug Name
Livdelzi (seladelpar)
Phase Of Trial
Phase 3
Enrolled
96
Alp normalization month1
52.3% (Livdelzi) vs 6.5% (placebo)
Alp normalization week52
75.4% (Livdelzi) vs 16.1% (placebo)

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    GILD: Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) — AI Analysis | Signal8